2026 Critical Care Congress Skip to main content
2026 Critical Care Congress Main banner
Final Program


Advance Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Thought Leader Session
Thought Leader Session
Guidelines Session
Guidelines Session
Aging Adult Track
Aging Adult Track
Additional Registration Fee
Additional Registration Fee

Research Snapshot Theater: Renal, Adult I

Clinical Validation of a Transdermal GFR Measurement System in Chinese Individuals

Tuesday, March 24, 2026
10:00 AM - 11:00 AM Central Time
Location: Connections Central - RST 15

  • Junfang Xu, N/A (she/her/hers)

    Zhejiang, CHN

    Disclosure(s): Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.: Employee (any industry) (Ongoing)

  • LZ

    Ling Zhang

    Disclosure information not submitted.

  • MZ

    Minghui Zhao, n/a

    Dr
    Peking University First Hospital

    Disclosure information not submitted.

  • YC

    Yimin Cui, n/a

    Dr
    Peking University First Hospital

    Disclosure information not submitted.

  • YL

    Yuanyuan Luo, N/A

    Dr
    The Affiliated of Xuzhou Medical Universty

    Disclosure information not submitted.

  • DS

    Dong Sun, N/A

    Dr
    The Affiliated Hospital of Xuzhou Medical University

    Disclosure information not submitted.

  • PF

    Ping Fu, N/A

    Dr
    West China Hospital, Sichuan University

    Disclosure information not submitted.

  • PF

    Ping Feng, N/A

    Dr
    West China Hospital, Sichuan University

    Disclosure information not submitted.

  • XZ

    Xia Zhao, N/A

    Dr
    Peking University First Hospital

    Disclosure information not submitted.

  • DL

    Dongmei Lan, N/A

    Dr
    The Affiliated of Xuzhou Medical Universty

    Disclosure information not submitted.

  • LC

    Limin Chen, N/A

    Mrs
    Hangzhou Zhongmeihuadong Pharmaceutical Co., LTD

    Disclosure information not submitted.

  • JZ

    Jun Zhou, N/A

    Mr
    Hangzhou Zhongmeihuadong Pharmaceutical Co., LTD

    Disclosure information not submitted.

  • JY

    Jiaxi Yue, N/A

    Mrs
    Hangzhou Zhongmeihuadong Pharmaceutical Co., LTD

    Disclosure information not submitted.

  • YL

    Ying Ling, N/A

    Mrs
    Hangzhou Zhongmeihuadong Pharmaceutical Co., LTD

    Disclosure information not submitted.

  • CZ

    Chaonan Zhu, N/A

    Mrs
    Hangzhou Zhongmeihuadong Pharmaceutical Co., LTD

    Disclosure information not submitted.

  • ZC

    Zhen Cao, N/A

    Mr
    Hangzhou Zhongmeihuadong Pharmaceutical Co., LTD

    Disclosure information not submitted.

  • RL

    Ran Li, N/A

    Mrs
    Hangzhou Zhongmeihuadong Pharmaceutical Co., LTD

    Disclosure information not submitted.

Introduction: A prior global study confirmed the safety and efficacy of MB-102 and the MediBeacon® Transdermal Glomerular Filtration Rate Measurement System (TGFR) in American and Chinese populations. Given variability in Fitzpatrick skin types (FSS) across ethnicities, further analysis was warranted to assess the performance of MB-102 and TGFR specifically in Chinese individuals.


Methods: This post hoc analysis of trial (NCT05425719) enrolled Chinese subjects with varying renal function, stratified by baseline estimated GFR (eGFR) into Cohort 1 (≥70 mL/min/1.73m²) and Cohort 2 ( < 70 mL/min/1.73m²). Participants received a single intravenous dose of 130 mg MB-102. Plasma GFR (nGFR) was derived via systemic clearance using a two-compartment pharmacokinetic (PK) model. Concurrently, continuous transdermal GFR (tGFR) was recorded using the TGFR system. The primary endpoint was P30, the proportion of tGFR values within ±30% of body surface area-indexed nGFR (nGFRBSA).


Results: The safety set (SS) and modified intent-to-measure set (mITMS) included 54 and 49 participants, respectively; 96.3% in the SS were FSS I-III. In the mITMS, median nGFRBSA and tGFR were 73.081 (range: 22.73-118.29) and 74.056 (range: 27.80-140.00) mL/min/1.73m². The P30 was 98.0% (95% CI: 89.1-99.9), exceeding the predefined 85% threshold and consistent with global findings. Bland-Altman analysis showed a mean bias (tGFR - nGFRBSA) of 0.07 mL/min/1.73m² with 95% limits of agreement (LoA) from -18.78 to 18.64. In Cohorts 1 and 2, mean differences were -2.06 (LoA: -26.42 to 22.30) and 2.01 (LoA: -6.78 to 10.80), respectively. Four subjects fell outside the ±1.96 standard deviation range. Regression analysis yielded a slope of 0.89 (95% CI: 0.80-0.98) and intercept of 7.70. The intraclass correlation coefficient between tGFR and nGFRBSA was 0.945. Treatment-emergent adverse events occurred in 3.7% of subjects, with no serious, device-related, or drug-related events reported.


Conclusions: This analysis confirms high concordance between transdermal and plasma MB-102 clearance in Chinese subjects with diverse renal function. TGFR plus MB-102 offers a safe, accurate, non-invasive option for real-time GFR monitoring, supporting its clinical application in this population.